← Torna allo Screener

Acadia Pharmaceuticals

ACAD Mid Cap

Healthcare · Biotechnology

Aggiornato: May 2, 2026, 22:05 UTC

18,72 €
-2.23% oggi
52W: 12,33 € – 24,18 €
52W Low: 12,33 € Posizione: 54% 52W High: 24,18 €

Metriche Chiave

P/E Ratio
9.54x
Rapporto P/E
Forward P/E
23.03x
P/E Forward
P/S Ratio
3.51x
Prezzo/Vendite
EV/EBITDA
25.52x
Valore Impresa/EBITDA
Rendimento Dividendi
Rendimento annuale da dividendi
Cap. di Mercato
3,2 Mrd. €
Capitalizzazione di Mercato
Crescita Ricavi
9.4%
Crescita Ricavi Anno su Anno
Margine di Profitto
36.49%
Margine Netto
ROE
39.89%
Return on Equity
Beta
0.83
Sensibilità al mercato
Interesse Corto
10.04%
% del flottante in vendita allo scoperto
Volume Medio
1,823,148
Volume Medio Giornaliero

Analisi della Valutazione

Segnale
Sottovalutata
vs. P/E medio S&P 500 (24,7x)
Consenso degli Analisti
Comprare
20 analisti
Prezzo Obiettivo Medio
27,04 €
+44.42% potenziale
Range Obiettivo
14,50 € – 38,39 €

Informazioni sull'Azienda

Settore: Healthcare Industria: Biotechnology Paese: United States Dipendenti: 796 Borsa: NMS

Acadia Pharmaceuticals Stock at a Glance

Acadia Pharmaceuticals (ACAD) is currently trading at 18,72 € with a market capitalization of 3,2 Mrd. €. The trailing P/E ratio stands at 9.54x, with a forward P/E of 23.03x. The 52-week range spans from 12,33 € to 24,18 €; the current price is 22.6% below the yearly high. Year-over-year revenue growth stands at +9.4%. The net profit margin stands at 36.49%.

💰 Dividendo

Acadia Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Raccomandazioni degli Analisti

20 analysts rate Acadia Pharmaceuticals (ACAD) on consensus: Comprare. The average price target is 27,04 €, implying +44.42% from the current price. Analyst price targets range from 14,50 € to 38,39 €.

Tesi di Investimento: Punti di Forza e Debolezze

Punti di Forza
  • Profitable with 36.49% net margin
  • High return on equity (39.89% ROE)
  • High gross margin of 61.01% — indicates pricing power
  • Analyst consensus: Buy
  • Currently flagged as undervalued
  • Solid balance sheet with low debt (D/E 4.25)
Debolezze
  • High short interest (10.04%)
  • Negative free cash flow

Panoramica Tecnica

MM 50 Giorni
18,93 €
-1.08% vs. prezzo
MM 200 Giorni
20,26 €
-7.58% vs. prezzo
Sotto Massimo 52S
−22.6%
24,18 €
Sopra Minimo 52S
+51.9%
12,33 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profilo di Rischio

Rischio di Mercato (Beta)
0.83 · Market-like
Moves less than the overall market
Short Interest
10.04% · High
% del flottante in vendita allo scoperto
Debt-to-Equity
4.25 · Low
Debito totale / patrimonio

The data points to relatively defensive market behavior, elevated short interest (10.04%).

Dati di Trading

50-Day MA: 18,93 €
200-Day MA: 20,26 €
Volume: 1,102,977
Volume Medio: 1,823,148
Ratio Corto: 5.87
Rapporto P/B: 3.05x
Debito/Patrimonio: 4.25x
Flusso di Cassa Libero: -46.763.734 €

Where can I buy Acadia Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top